Loading…
BlossomHill Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in BLSM.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DCTHDelcath Systems Inc | $16.34 | 1634.0x | 4.7x | — | 0.47% | $566.98M |
| TLRYTilray Brands, Inc. | $4.02 | — | 0.3x | — | -6.82% | $564.5M |
| BWAYBrainsway Ltd. | $14.30 | 62.2x | 7.0x | — | 12.82% | $574.7M |
| ALLOAllogene Therapeutics, Inc. | $1.67 |
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Company description provided by Yahoo Finance.
| — |
| 1.3x |
| — |
| -42.39% |
| $576.97M |
| MPLTMapLight Therapeutics, Inc. | $12.60 | — | 1.6x | — | -111.55% | $584.36M |
| FLGTFulgent Genetics, Inc. | $21.27 | — | 0.6x | — | -8.11% | $585.25M |